Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75,078 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D, So K, Dymond AW, Vik T, Al-Huniti N, Mariani G, Zorenyi G, Huang Y, Holmes V, Severin P, Rasmussen S, Martin P. Zhou D, et al. Among authors: huang y. Clin Ther. 2016 Dec;38(12):2555-2566. doi: 10.1016/j.clinthera.2016.10.004. Epub 2016 Nov 9. Clin Ther. 2016. PMID: 27837934 Free article. Clinical Trial.
Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW, So K, Martin P, Huang Y, Severin P, Mathews D, Lisbon E, Mariani G. Dymond AW, et al. Among authors: huang y. Eur J Clin Pharmacol. 2017 Feb;73(2):175-184. doi: 10.1007/s00228-016-2153-7. Epub 2016 Nov 26. Eur J Clin Pharmacol. 2017. PMID: 27889832 Free PMC article. Clinical Trial.
Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
Dymond AW, Martin P, So K, Huang Y, Severin P, Holmes V, Mariani G, Marbury T. Dymond AW, et al. Among authors: huang y. J Clin Pharmacol. 2017 May;57(5):592-605. doi: 10.1002/jcph.848. Epub 2016 Dec 26. J Clin Pharmacol. 2017. PMID: 28019010 Free PMC article. Clinical Trial.
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia.
Dillon LW, Gui G, Ravindra N, Andrew G, Mukherjee D, Wong ZC, Huang Y, Gerhold J, Holman M, D'Angelo J, Miller J, Higgins J, Salk JJ, Auletta JJ, El Chaer F, Devine SM, Jimenez-Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Hourigan CS. Dillon LW, et al. Among authors: huang y. JAMA Oncol. 2024 May 2. doi: 10.1001/jamaoncol.2024.0985. Online ahead of print. JAMA Oncol. 2024. PMID: 38696205
75,078 results
You have reached the last available page of results. Please see the User Guide for more information.